

Thijs J Giezen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9788585/publications.pdf>

Version: 2024-02-01

11
papers

187
citations

1937632

4
h-index

1372553

10
g-index

11
all docs

11
docs citations

11
times ranked

238
citing authors

#	ARTICLE	IF	CITATIONS
1	Interchangeability of Biosimilars: A European Perspective. <i>BioDrugs</i> , 2017, 31, 83-91.	4.6	153
2	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105501.	4.0	11
3	QTc Prolongation in COVID-19 Patients Using Chloroquine. <i>Cardiovascular Toxicology</i> , 2021, 21, 314-321.	2.7	5
4	Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. <i>Pharmaceuticals</i> , 2021, 14, 189.	3.8	4
5	The effect of medication related clinical decision support at the time of physician order entry. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 137-143.	2.1	3
6	Switching TNF $\hat{\pm}$ inhibitors: Patterns and determinants. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00843.	2.4	3
7	Patients Retransitioning from Biosimilar TNF $\hat{\pm}$ Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. <i>BioDrugs</i> , 2022, 36, 27-39.	4.6	3
8	Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1457-1464.	1.9	2
9	Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. <i>Biologicals</i> , 2021, 69, 30-37.	1.4	2
10	Nature and timing of post-approval manufacturing changes of tumour necrosis factor $\hat{\pm}$ inhibitor products: A 20-year follow-up study of originators and biosimilars. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 175, 106227.	4.0	1
11	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept. <i>BioDrugs</i> , 2021, 35, 765-772.	4.6	0